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Background: The National Tuberculosis and Leprosy Control Program (NTBLCP) in collaboration with Koninklijke 
Nederlandse Centrale Vereniging tot bestrijding der tuberculose (KNCV) (Dutch Tuberculosis Foundation) and 
National Agency for Control of AIDS (NACA) installed and equipped many health centres in Kaduna State, Nigeria 
with modern diagnostic tools (GeneXpert) to offer molecular services for the rapid detection of Mycobacterium 
tuberculosis complex (MTBC) and rifampin resistance.                     
Methodology: This study analyzed routine samples from patients attending General Hospital Kagarko, from 
September 2016 to March 2019 with total samples of 1056 from 1056 patients. The GeneXpert machine was used 
for the rapid detection of M. tuberculosis and rifampin resistance (RIF) from all the sputum samples received in the 
clinical laboratory department of the hospital.                            
Results: A total of 182 (17.2%) samples tested positive for M. tuberculosis out of which 5 (2.7%) were resistant 
to rifampicin. Males were more frequently affected with a prevalence of 23% than females with a rate of 10.7% 
(X2=27.801, p=0.0001). RIF was detected in 3 male and 2 female patients (p=1.000). The prevalence of MTB was 
highest in the age group 36-45 years (23%) and age group 26-35 years (20.3%) and lowest in age group 5-15 
years with 10.9% (t=0.599, p=0.55).                           
Conclusion: There is need for the GeneXpert technology to be replicated in other health centers across the state 
and the country at large to reduce the burden of multi-drug resistant tuberculosis (MDR-TB) in Nigeria. 
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Abstrait: 
Contexte: Le programme national de lutte contre la tuberculose et la lèpre (NTBLCP) en collaboration avec 
Koninklijke Nederlandse Centrale Vereniging tot bestrijding der tuberculose (KNCV) (Fondation néerlandaise pour la 
lutte contre la tuberculose) et l'Agence nationale de lutte contre le sida (NACA) ont installé et équipé de nombreux 




centres de santé dans l'État de Kaduna , Nigeria, avec des outils de diagnostic modernes (GeneXpert) pour offrir 
des services moléculaires pour la détection rapide du complexe Mycobacterium tuberculosis (MTBC) et la résistance 
à la rifampicine.                           
Méthodologie: Cette étude a analysé des échantillons de routine de patients fréquentant l'hôpital général de 
Kagarko, de septembre 2016 à mars 2019, avec des échantillons totaux de 1056 sur 1056 patients. L'appareil 
GeneXpert a été utilisé pour la détection rapide de M. tuberculosis et de la résistance à la rifampicine (RIF) pour 
tous les échantillons d'expectorations reçus dans le service de laboratoire clinique de l'hôpital.                        
Résultats: Un total de 182 échantillons (17,2%) ont été testés positifs pour M. tuberculosis, dont 5 (2,7%) étaient 
résistants à la rifampicine. Les hommes étaient plus fréquemment touchés avec une prévalence de 23% que les 
femmes avec un taux de 10,7% (X2=27,801, p=0,0001). Le RIF a été détecté chez 3 hommes et 2 femmes 
(p=1.000). La prévalence du VTT était la plus élevée dans le groupe d'âge 36-45 ans (23%) et le groupe d'âge 26-
35 ans (20,3%) et la plus faible dans le groupe d'âge 5-15 ans avec 10,9% (t=0,599, p=0,55).                        
Conclusion: Il est nécessaire que la technologie GeneXpert soit reproduite dans d'autres centres de santé de l'État 
et du pays dans son ensemble pour réduire le fardeau de la tuberculose multirésistante (TB-MR) au Nigéria. 
Mots-clés: résistance au RIF, TB-MR, GeneXpert, Mycobacterium tuberculosis 
Introduction: 
 Drug-resistant tuberculosis (DR-TB) is 
a tuberculous disease resulting from 
Mycobacterium tuberculosis resistant to at 
least one first-line anti-TB drug; isoniazid 
(INH) and rifampicin (RIF). Drug resistant TB 
could be mono-resistance in which there is 
resistance to only one first-line anti-TB drug or 
poly-resistance in which there is resistance to 
more than one first-line anti-TB drugs other 
than isoniazid and rifampicin (1,2). Multidrug 
resistance (MDR) is defined as resistance to at 
least both isoniazid and rifampicin, and 
extensively drug resistance (XDR) as resis- 
tance to any fluoroquinolone, and at least one 
of three second-line injectable drugs 
(capreomycin, kanamycin and amikacin) in 
addition to multidrug resistance (2,3). 
Rifampicin resistance (RR) is resistance to 
rifampicin, detected by phenotypic or geno- 
typic methods, with or without resistance to 
other anti-TB drugs, and includes mono- 
resistance to rifampicin (2,4).    
 The World Health Organization (WHO) 
estimates that TB kills approximately 2 million 
people worldwide each year, and MDR-TB is 
becoming an increasing public health challenge 
in many parts of the world, basically due to 
poor patient adherence to the six-month 
tuberculosis treatment regimen. About 5% of 
all TB cases are reported to be MDR-TB (2). 
Resistance to rifampin is one of the primary 
reasons for treatment failure and fatal clinical 
outcome in TB patients (4,5).   
 Treatment of drug-resistant TB is 
difficult and inappropriate management can 
lead to life-threatening outcomes (1,6). The 
traditional method for diagnosis of drug 
resistant TB is usually by susceptibility testing 
involving the growth of M. tuberculosis on 
liquid or solid culture medium, which takes 
about 2 months. Culture methods are 
expensive and time consuming, thus delay 
opportunity for prompt treatment of patients. 
With the recent development of nucleic acid 
amplification technologies, which are rapid, 
sensitive, and specific, opportunity of timely, 
accurate and precise diagnosis of drug 
resistant TB is broadened (3,7). The GeneXpert 
assay uses real-time polymerase chain reaction 
(PCR) technology to simultaneously amplify 
and detect M. tuberculosis-specific sequence of 
the rpoB gene (1,6).     
 Rifampicin has significant early 
bactericidal effect on metabolically active M. 
tuberculosis and excellent terminal removal 
activity on low inactive micro-organisms 
passing through short bursts of metabolic 
activity. The mechanism of action of rifampicin 
is inhibition of mycobacterial transcription by 
targeting DNA dependent RNA polymerase 
Resistance to rifampicin develops from 
mutations within the 27 codons in the well-
defined 81 base pair (bp) central region of the 
gene (rpoB) that encodes the β-subunit of RNA 
polymerase. More than 96% of the rifampicin-
resistant strains contain a mutation in this 
region thus facilitating a straightforward rapid 
approach for detecting rifampicin resistance 
and/or MDR (3,8,9). Therefore, the aim of this 
study was to determine the prevalence of 
rifampicin resistance in TB patients attending 
General Hospital, Kagarko using the GeneXpert 
MTB/RIF assay. 
Materials and methods: 
 
Study setting 
 The study was conducted in General 
Hospital, Kagarko in Kagarko Local Govern- 
ment Area (LGA) of Kaduna State, Nigeria. The 
laboratory department of the hospital receives 
samples within the hospital covering the entire 
LGAs and from other health facilities in 
neighboring LGAs. 





 This study population was made of 
patients who presented with cough of two or 
more weeks duration and referred to the 
clinical laboratory department of the hospital 
for sputum examination by the GeneXpert 
assay between November 2016 and March 
2019. One sputum sample was collected per 
patient according to the GeneXpert sample 
collection guidelines, and the total number of 
patients was 1056. 
 
Ethical approval 
 The study was approved by the 
Research and Ethics Committee of the Kaduna 
State Ministry of Health and Human services. 
 
Laboratory analysis by GeneXpert assay  
 Sample reagent was added to sputum 
sample in a 2:1 ratio and in a 3:1 ratio to 
suspended sediment of decontaminated or 
digested sputum specimen. The lid of the 
sputum container was replaced, and manually 
shaken vigorously 10-20 times (one back and 
forth movement in single shake), and incu- 
bated at room temperature for 10 minutes. 
This was again shaken vigorously 10-20 times 
(or vortex) and further incubated for 5 minutes 
at room temperature with samples perfectly 
fluidics with no visible clumps of sputum at the 
end of incubation.  
 The cartridges were labeled appro- 
priately on the left or right side with sample 
ID. Two ml of the prepared sputum samples 
were transferred to the cartridges using 
transfer pipette with avoidance of solid 
particles and aerosols or bubbles. The lids of 
the cartridges were firmly closed and then 
inserted into the test platform located in the 
clean room. The test platform (Cepheid) is the 
integrated diagnostic device that performs 
sample processing and simultaneous amplifi- 
cation and detection of fluorescence (real-time 
polymerase chain reaction; rt-PCR) in a single 
hands-free step for the identification of M. 
tuberculosis and simultaneous rapid detection 
of rifampicin (RIF) resistance in the sputum 
specimens. The electronic results were sent 
directly from the MTB/RIF test system to the 
central database in about 120 minutes. 
 
Statistical analysis 
 Data were entered into Microsoft 
Access (Microsoft Corp., Redmond, WA, USA) 
and analyzed with Microsoft Excel. Comparison 
of the prevalence of MTB and rifampin 
resistance with respect to age group and 
gender of patients was done with Chi square 




 This study included 1056 patients (568 
males, 488 females) with presumptive TB 
whose sputum samples (one sample per 
patient) were received and tested at the 
clinical laboratory department of General 
Hospital Kagarko, Kaduna State between 
September 2016 and March 2019. A total of 
182 (17.2%) sputum specimens were positive 
for M. tuberculosis with the GeneXpert 
MTB/RIF assay including 5 (0.5%) that were 
rifampicin resistant, while 874 (82.7%) were 
negative (Table 1).  
 The prevalence of TB was significantly 
higher in the male patients with 23% (130 of 
568) than the female patients with 10.7% 
(52/488) (p=0.0001) but the rifampicin 
resistance rate of 0.5% (3/568) in the male 
was not significantly different from 0.4% 
(2/488) in the female patients (p=1.000) 
(Table 1).  
 The prevalence of TB in relation to the 
age group showed that age group 36–45 years 
had the highest MTB detected with 23% 
(43/187), followed by age group 26–35 years 
with 20.3% (53/261), age group 46–55 years 
18.4% (27/147), age group > 55 years 14.8% 
(27/199), age group 16–25 years 12.8% 
(23/180) and age group 5-15 years 11% 




Table 1: Frequency distribution of MTB detection by GeneXpert with respect to gender of patients  
 
Gender No tested MTB positive (%) MTB Rif Resist (%)  Total (%)  χ2 p value 
Male    568                 127 (22.4)     3 (0.5)              130 (23) 27.801 0.0001* 
Female    488                  50 (10.2)     2 (0.4)             52 (10.7) 
Total    1056                 177 (16.8)     5 (2.7)               182 (17.2) 
*p<0.05 – statistically significant for MTB; X2 = Chi square  




Table 2: Frequency distribution of MTB detection by GeneXpert with respect to age group of patients  
Age group (years) No tested MTB positive (%)    t df CI   p value 
5 – 15                     82                  9 (11.0)         0.599  288.9 0.159-0.299 0.55* 
16 – 25                   180                  23 (12.8)            
26 – 35                   261                  53 (20.3)             
36 – 45                   187                     43 (23.0) 
46 – 55                   147                     27 (18.4) 
> 55                    199                      27 (13.6) 
Total                          1056                       182 (17.2) 




 MDR TB has become a serious public 
health challenge globally but especially in 
developing countries (10). The GeneXpert MTB 
/RIF assay has opened up opportunity for the 
rapid detection of MTB and resistance to 
primary anti-TB drugs (11). In this study, MTB 
was detected by the GeneXpert in 17.2% of 
the 1056 sputum specimens obtained from 
patients with presumptive TB among whom 5 
(2.7%) were rifampicin resistant MTB. Majority 
of the MTB patients were between the age 
groups 36-45 (23%) and 26-35 years 
(20.3%), which is generally considered the 
active and vulnerable age group to MTB 
infections. Also, the prevalence rate of TB by 
the GeneXpert assay in males (23%) was 
significantly higher than in females (10.7%) 
(p=0.0001). The difference could be related to 
social attitude of the males which make them 
more exposed and vulnerable to MTB infection 
than the females. 
  Otu et al., (12) in their study reported 
drug resistance rate of 42% to at least one 
anti-TB drug on mycobacterial culture in 
patients with pulmonary TB in Calabar, south-
south Nigeria. They found mono-resistance 
rate of 7% to ethambutol and 7% to strepto- 
mycin but none to rifampicin. The difference in 
methods of testing for rifampicin resistance 
does not allow for direct comparison as we 
used GeneXpert MTB/RIF assay in our study 
which is programmed to detect only rifampicin 
resistance. The rifampicin resistance rate of 
2.7% reported in our study is lower than the 
14.7% reported by Ikuabe and Ebuenyi (1) in 
Yenagoa using GeneXpert MTB/RIF assay. 
 The low rifampicin resistance rate in 
our study may be related to the new history of 
use of rifampicin in this part of the country and 
Africa as a continent (12) but differences in 
rates may also be related  to  level  of patients’  
 
 
awareness, compliance/adherence to anti-TB 
drugs and geographical location. Poor manag- 
ement of active pulmonary TB is a known 
factor for emergence of drug resistant TB, 
which could be aided by several factors such as 
poor prescribing practices with insufficient 
treat- ment duration and poor drug compliance 
by patients (13). Other factors include poor 
public health awareness and financial 
resources, shortages in drug supplies to 
directly observed treatment (DOT) centres and 
lack of proper health education of patients on 
the medication (11, 13). Rifampicin resistance 
rate in our study was not associated with 
gender and age group as the rate of 0.5% in 
the males was not significantly different from 
the rate of 0.4% in the females (p=1.000), 
however, this result should be interpreted with 
caution because of the small number of 
patients with RIF in this study.  
 Conventional laboratory techniques 
such as microscopy for detection of acid-fast 
bacilli (AFB) in sputum samples for the 
diagnosis of tuberculosis are far from being 
sensitive. Moreover, mycobacterial cultures are 
time-consuming, require biosafety measures, 
and need trained laboratory personnel. In our 
study, the GeneXpert assay used have been 
reported to be highly sensitive and specific 
(over 97%) for TB diagnosis from pulmonary 
specimens, and generate results rapidly, 
therefore reducing the turn-around time for TB 
diagnosis (14). The GeneXpert assay also 
targets the region of rifampicin resistance 
associated rpoB gene by real-time polymerase 
chain reaction (rt-PCR) with three specific 
primers that simultaneously detect M. tubercu- 
losis DNA and rifampicin resistance. The 
processes of bacterial lyses, DNA extraction, 
real time amplification and amplicon detection 
are automated, which give room for less 
interference and contamination.  




Conclusion:    
 
 The prevalence of MDR-TB as deter- 
mined by rifampicin resistance rate of 2.7% in 
our study emphasizes the need to make the 
GeneXpert MTB/RIF machines widely available 
to facilitate rapid detection of MDR-TB in 
Nigeria.  
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